A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.
An investigation of a novel, off-label use of an FDA approved drug (ketamine) in a low(micro) dose sublingual formulation of ketamine provided to front-line healthcare workers who were identified as suffering from acute stress disorder. The study was conducted completely virtually via real-time telemedicine for physician visits and via asynchronous interaction for outcomes data collection. Patients self-referred to the study via email outreach, and diagnosis was confirmed by medically validated screening assessments and study physician confirmation. Once treatment was initiated, patients were seen via live telemedicine every 40 days while treatment response/outcomes data was collected weekly and monthly. Patients were treated up to 120 days.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
Limbic Medical
Toluca Lake, California, United States
Patient self-reported outcome measure
Perceived Stress Scale
Time frame: up to 120 days
Patient self-reported outcome measure
15-Dimensional Health-Related Quality of Life Questionnaire 15-Dimensional Health-Related Quality of Life Questionnaire
Time frame: up to 120 days
Patient self-reported outcome measure
PCL-5 (PTSD checklist for DSM-5)
Time frame: up to 120 days
Patient self-reported outcome measure
Physical Health- NIH PROMIS Global
Time frame: up to 120 days
Patient self-reported outcome measure
Mental Health- NIH PROMIS Global
Time frame: up to 120 days
Patient self-reported outcome measure
Health Perception and Social Roles
Time frame: up to 120 days
Patient self-reported outcome measure
Doctor's Note
Time frame: up to 120 days
Patient self-reported outcome measure
NIH PROMIS CAT- Depression
Time frame: up to 120 days
Patient self-reported outcome measure
NIH PROMIS CAT Neuro-QOL-Anxiety
Time frame: up to 120 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.